The present invention provides a composition that contains γ-aminobutyric acid (GABA) as an active ingredient and is used for ameliorating or preventing confusion and/or bewilderment in a subject. The composition according to the present invention is preferably capable of ameliorating or preventing confusion and/or bewilderment evaluated by Profile of Mood States 2nd Edition (POMS2).
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
The present invention provides a method for producing a GABA-containing powder using a lactic acid bacterium, which enables the production of a GABA product having improved taste and/or odor. Specifically, the present invention provides a method for producing a γ-aminobutyric acid (GABA)-containing powder, the method comprising: (1) a fermentation step in which a lactic acid bacterium having GABA production capability is inoculated into a raw material and cultured to obtain a GAVA-containing fermented liquid; (2) a pH adjustment step in which the pH of the fermented liquid is adjusted to obtain a pH-adjusted fermented liquid; (3) a step in which the pH-adjusted fermented liquid is heated to obtain a heat-sterilized fermented liquid in which the lactic acid bacterium is sterilized; and (4) a step in which the heat-sterilized fermented liquid is treated with activated carbon.
Provided is a novel composition or method for inhibiting fibrosis. This composition for inhibiting fibrosis comprises an antibody that specifically binds to PAD2 and is used. In addition, a pharmaceutical composition for treating fibrotic disease comprises an antibody that specifically binds to PAD2 and a pharmaceutically acceptable carrier, and may be used. Further, a kit for inhibiting fibrosis comprises an antibody that specifically binds to PAD2 and may be used.
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Iwasaki, Yusaku
Sagane, Riho
Nakamura, Utano
Miyazaki, Maiko
Yamatsu, Atsushi
Kim, Mujo
Abrégé
According to the present invention, a composition that induces the feeling of satiety or suppresses binge eating is provided.
According to the present invention, a composition that induces the feeling of satiety or suppresses binge eating is provided.
The present invention provides a GABA-containing composition for inducing transient satiety in a subject. The present invention also provides a GABA-containing composition for suppressing binge eating on a fasting condition in a subject.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
The present invention provides: a method for dissolving a sparingly water-soluble protein; and a molded article made from a protein solution obtained by the method. The present invention provides: a method for dissolving a sparingly water-soluble protein, the method comprising a step for mixing together a hydroxyl group-containing polymer, a sparingly water-soluble protein, and an ionic liquid. Furthermore, the present invention makes it possible to produce a molded body from a sparingly water-soluble protein solution obtained by such method.
C08L 1/00 - Compositions contenant de la cellulose, de la cellulose modifiée ou des dérivés de la cellulose
C08L 29/04 - Alcool polyvinyliqueHomopolymères ou copolymères d'esters partiellement hydrolysés d'alcools non saturés avec des acides carboxyliques saturés
C08L 31/04 - Homopolymères ou copolymères de l'acétate de vinyle
The present invention provides a composition for inducing a flow (zone) state in a subject, the composition containing γ-aminobutyric acid (GABA). The composition according to the present invention is capable of inducing a subject, who is engaged in a specific operation or movement, into a flow (zone) state.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61P 25/26 - Psychostimulants, p. ex. nicotine, cocaïne
According to the present invention, GABA can be used in fields other than food. The present invention provides a plant growth-promoting composition containing GABA. By applying the GABA-containing composition according to the present invention to plants, a plant growth-promoting effect can be expected.
A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
A01G 7/06 - Traitement des arbres ou des plantes en cours de croissance, p. ex. pour prévenir la décomposition du bois, pour teinter les fleurs ou le bois, pour prolonger la vie des plantes
A01N 25/02 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des liquides comme supports, diluants ou solvants
A01P 21/00 - Régulateurs de croissance des végétaux
Provided is an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1, HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, HCDR3 comprises an amino acid sequence of SEQ ID NO: 3, LCDR1 comprises an amino acid sequence of SEQ ID NO: 4, LCDR2 comprises an amino acid sequence of SEQ TD NO: 5, and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6.
Provided is a novel antibody which may be used for the treatment of SARS-CoV-2. An antibody or an antigen-binding fragment thereof according to the present disclosure is an anti-CADM1 antibody or an antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of (Ca) and (Cb): (Ca) an antibody comprising the amino acid sequences of a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 represented by SEQ ID NOs:1, 2 and 3, respectively, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 represented by SEQ ID NOs:4, 5 and 6, respectively; and (Cb) a variant of (a) antibody including some of substitution, insertion, addition, or deletion in the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and/or the light chain CDR3.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
10.
METHOD FOR DISSOLVING SPARINGLY WATER-SOLUBLE PROTEIN, PROTEIN SOLUTION OBTAINED BY METHOD FOR DISSOLVING SPARINGLY WATER-SOLUBLE PROTEIN, AND MOLDED BODY OF PROTEIN SOLUTION OBTAINED BY METHOD FOR DISSOLVING SPARINGLY WATER-SOLUBLE PROTEIN
The present invention provides a method for dissolving a sparingly water-soluble protein and a method for producing a polymer molded body that contains a sparingly water-soluble protein. The present invention provides a method for dissolving a sparingly water-soluble protein, the method including a step for combining the sparingly water-soluble protein and a water-soluble tertiary amine oxide. The present invention also makes it possible to produce a molded body from a protein solution obtained by such a method.
C08J 3/205 - Formation de mélanges de polymères avec des additifs, p. ex. coloration en présence d'une phase liquide
C08J 3/02 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension
C08K 5/32 - Composés contenant de l'azote lié à l'oxygène
C08L 29/04 - Alcool polyvinyliqueHomopolymères ou copolymères d'esters partiellement hydrolysés d'alcools non saturés avec des acides carboxyliques saturés
C08L 89/00 - Compositions contenant des protéinesCompositions contenant leurs dérivés
Provided are a novel composition and method for inhibiting fibrosis. A composition for inhibiting fibrosis containing an antibody that specifically binds to PAD2 is used. Alternatively, a pharmaceutical composition for treating fibrosis containing an antibody that specifically binds to PAD2 and a pharmaceutically acceptable carrier may be used. Alternatively, a kit for inhibiting fibrosis containing an antibody that specifically binds to PAD2 may be used.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
The present invention relates to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Iwasaki, Yusaku
Sagane, Riho
Nakamura, Utano
Miyazaki, Maiko
Yamatsu, Atsushi
Kim, Mujo
Abrégé
According to the present invention, provided is a composition for inducing satiety or suppressing overeating. This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provides a GABA-containing composition for suppressing overeating in a subject when the subject is hungry.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/7016 - Disaccharides, p. ex. lactose, lactulose
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
14.
RECYCLED CELLULOSE FIBERS, METHOD FOR PRODUCING SAME, AND FIBER STRUCTURE OF SAME
The present invention provides highly safe functional fibers by imparting a novel function to recycled cellulose fibers. The present invention provides recycled cellulose fibers which contain an eggshell membrane hydrolysate. The recycled cellulose fibers according to the present invention may contain about 0.5 part by mass to about 25 parts by mass of the eggshell membrane hydrolysate per about 100 parts by mass of cellulose.
MITSUBISHI CORPORATION LIFE SCIENCES LIMITED (Japon)
Inventeur(s)
Yamatsu, Atsushi
Nakamura, Utano
Sakata, Tomoko
Kim, Mujo
Yokoyama, Yasuhiro
Abrégé
Provided is a novel composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing γ-aminobutyric acid.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
17.
CERAMIDE-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME
Provided is a composition containing a ceramide derived from a natural substance. The present invention provides a composition containing a polyphenol and a ceramide. The invention of the present application further provides a composition containing a ceramide derived from wine fermentation lees. Also provided is a method for producing a ceramide-containing composition, the method comprising a step for washing wine fermentation lees and a step for extracting the resulting washing residue using a polar solvent.
The present invention addresses the problem of providing a novel method for producing a γ-aminobutyric acid (GABA) powder and a product that contains a GABA powder produced by the production method. The present invention provides a method for producing a GABA-containing powder, said production method comprising: (1) a fermentation step for inoculating a lactic acid bacterium capable of producing GABA into a starting material and culturing to give a GABA-containing fermented liquid; (2) a heat sterilization step for heating the fermented liquid to sterilize the lactic acid bacterium; (3) a step for adding an excipient to the fermented liquid; (4) a heating and mixing step for mixing the fermented liquid, which contains the excipient added thereto, under heating to give a liquid mixture; (5) a standing step for allowing the liquid mixture to stand still; and (6) a spray-drying step for spray-drying the liquid mixture to give the GABA-containing powder.
A61K 8/44 - Acides aminocarboxyliques ou leurs dérivés, p. ex. acides aminocarboxyliques contenant du soufreLeurs sels, esters ou dérivés N-acylés
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
The present invention provides a whitening agent which is highly safe and also has an excellent whitening effect. The present invention provides a skin whitening composition containing trehalose as an active ingredient. The present invention also provides a method for improving the brightness of the skin, the method comprising a step for applying a skin whitening composition containing trehalose as an active ingredient.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid sequence of SEQ ID NO: 4, LCDR2 includes an amino acid sequence of SEQ ID NO: 5, and LCDR3 includes an amino acid sequence of SEQ ID NO: 6, or an antibody fragment thereof.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention provides a composition characterized by containing two or more selected from the group consisting of Bifidobacteria or culture solutions thereof, glutamic acid, or polymers or salts thereof, and rice bran-derived fermented products, as well as an agent for promoting Staphylococcus epidermidis proliferation, suppressing Staphylococcus aureus proliferation or improving bacterial flora, or an agent for preventing or alleviating dandruff, itching or hair loss of a head, the agent containing the composition.
The present invention pertains to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.
A61K 31/231 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone ayant une ou deux doubles liaisons
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Iitsuka, Hiroaki
Kim, Yugweng
Sakashita, Maya
Yamatsu, Atsushi
Kim, Mujo
Aoi, Wataru
Abrégé
[Technical Problem]
To provide a novel composition for more efficiently improving endurance than the conventional art.
[Solution to Problem]
A composition for improving endurance, comprising γ-aminobutyric acid.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
MITSUBISHI CORPORATION LIFE SCIENCES LIMITED (Japon)
Inventeur(s)
Yamatsu, Atsushi
Nakamura, Utano
Sakata, Tomoko
Kim, Mujo
Yokoyama, Yasuhiro
Abrégé
Provided is a novel composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing γ-aminobutyric acid.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
25.
Fat absorption inhibiting agent, food and defatted sesame seeds, and method for inhibiting obesity
Problem to be solved: An object of the present invention is to provide a novel fat absorption inhibiting agent.
Solution to the problem: The present invention provides a fat absorption inhibiting agent comprising pulverized defatted sesame seeds or a processed product thereof. The present invention also provides a fat absorption inhibiting agent comprising defatted sesame seeds having a 50th percentile particle size of 1 to 200 μm as determined by laser diffraction/scattering and a compressibility index of 30 to 80%. The fat absorption inhibiting agent of the present invention preferably has lipase inhibitory activity. The present invention also provides a food comprising the agent. The present invention also provides defatted sesame seeds having a 50th percentile particle size of 1 to 200 μm as determined by laser diffraction/scattering and a compressibility index of 30 to 80%. The present invention provides a method for inhibiting obesity in a human or animal, the method comprising administering to a human or animal the agent, the food or the defatted sesame seeds.
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 25/00 - Aliments contenant principalement des noix ou des grainesLeur préparation ou leur traitement
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
26.
VITELLINE MEMBRANE- AND/OR CHALAZA-DERIVED COSMETIC COMPOSITION, AND METHOD FOR PRODUCING SAME
Provided is a novel utilization of the vitelline membrane and chalaza occurring as waste produced in liquid egg production processes. This cosmetic composition is a cosmetic composition for improving the condition of the skin and comprises a poultry-derived vitelline membrane component and/or chalaza component.
A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
A61K 35/57 - OiseauxSubstances provenant des oiseaux, p. ex. œufs, plumes, blanc d’œuf, jaune d’œuf ou endothelium corneum gigeriae galli
To obtain an anti-PAD2 antibody having excellent PAD2 inhibitory activity. Provided is an anti-PAD2 antibody that specifically binds to positions 341 to 357 of PAD2. Also provided is an anti-PAD2 antibody that specifically binds to a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1.
Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés
C07K 5/04 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés ne comportant que des liaisons peptidiques normales
Provided is an anti-PAD2 antibody which has excellent PAD2 inhibitory activity. The used anti-PAD2 antibody specifically binds to positions 341-357 of PAD2 or specifically binds to a peptide having an amino acid sequence indicated by SEQ ID NO: 1.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Gamma-aminobutyric acid (GABA) for use as a food additive; Fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive Dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid, and gelled form
An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.
A61K 8/65 - CollagèneGélatineKératineLeurs dérivés ou produits de dégradation
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
A23C 19/00 - FromagePréparations à base de fromageFabrication de ces produits
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61Q 19/00 - Préparations pour les soins de la peau
A61Q 19/08 - Préparations contre le vieillissement
33.
BIOMARKER FOR PREDICTING THERAPEUTIC EFFECT OF FSTL1 INHIBITOR IN CANCER PATIENT
A method for predicting the therapeutic effect of a FSTL1 inhibitor in a cancer patient, said method being characterized by comprising the steps of: (1) measuring the expression level of FSTL1 and/or DIP2A in a sample collected from the patient; (2) comparing a measurement value with a reference value; and (3) determining that the therapeutic effect is promised when the measurement value is higher than the reference value. For example, according to the present invention, a companion diagnosis for predicting the efficacy or the like of a treatment with a FSTL1 inhibitor can be performed suitably.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
34.
Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A preventative and/or therapeutic agent for osteogenesis imperfecta, osteoporosis and/or osteoarthritis containing a peptide consisting of an amino acid sequence shown by (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) or (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). This agent can be taken orally, has osteogenic function, and has a preventative and/or healing-promoting effect on bone fractures and is therefore very useful in the prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.
The present invention provides a hair regrowth promoter comprising an egg-yolk protein hydrolysate as an active ingredient. The egg-yolk protein hydrolysate is a safe ingredient produced from a natural source, and therefore can be widely used in daily consumable products, such as food and drink products, medicaments, animal feeds, and dietary supplements, or as a food additive, etc. The promoter etc. of the present invention can be orally administered and is thus very advantageous.
A23L 27/21 - Épices, agents aromatiques ou condiments synthétiques contenant des acides aminés
A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
A61K 35/57 - OiseauxSubstances provenant des oiseaux, p. ex. œufs, plumes, blanc d’œuf, jaune d’œuf ou endothelium corneum gigeriae galli
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
37.
Peptides having osteoblast growth-promoting activity and use thereof
The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from
(a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO: 1),
(b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
(c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or
a derivative thereof or a salt thereof.
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japon)
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (Japon)
PHARMA FOODS INTERNATIONAL CO., LTD. (Japon)
Inventeur(s)
Sato, Mamoru
Yamada, Michiyuki
Kanazawa, Satoshi
Toyoura, Masayoshi
Shoya, Yuji
Saito, Kenji
Yamazaki, Chihiro
Abrégé
Acquired are an anti-PAD4 antibody having exceptional characteristics, or an exceptional method for treating RA. An anti-PAD4 antibody is used that binds specifically to an epitope including positions 345, 347, and 348 of PAD4. This anti-PAD4 antibody may inhibit the citrulline activity of PAD4. The KD (M) of this anti-PAD4 antibody may also be 9.0 × 10-9 or less. Alternatively, an anti-PAD4 antibody and a TNFα inhibitor may be used in combination.
The present invention provides an anti-FSTL1 antibody, or a fragment or functional equivalent thereof, said antibody having an- epitope in a site selected from a group consisting of positions 48-100, 148-162, 193-216, 205-228 or 272-289 of the amino acid of SEQ ID NO:1 (human FSTL1 amino acid sequence). Also provided is an agent obtained by combining an FSTL1 suppressor and another anti-cancer agent. The present invention is understood to effectively eliminate immunosuppression, immunodeficiency and other forms of immune breakdown.
An agent containing a poultry leg or a treatment product thereof, preferably a hydrolysate of an extract of a poultry leg, can promote the production of hyaluronic acid, has an excellent prophylactic or therapeutic effect on joint disorders and also has an effect of improving dryness, wrinkling or tenseness of skin, an effect of moisturizing skin and the like, and is therefore useful as a drug, a quasi drug, a cosmetic, a food or a feed.
The present invention provides a hair growth promoter containing an egg-yolk protein hydrolysate as an effective component thereof. The egg-yolk protein hydrolysate is a naturally-derived, safe, and used widely as a food and beverage item suitable for daily consumption and in pharmaceuticals, animal fodder, supplements, and food additives, etc. In addition, the present invention is particularly useful as a result of being capable of being orally administered.
NATIONAL RESEARCH AND DEVELOPMENT AGENCY NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japon)
PHARMA FOODS INTERNATIONAL CO., LTD. (Japon)
Inventeur(s)
Uchida, Yuko
Saito, Takehiko
Suzuki, Yasushi
Shoya, Yuji
Toyoura, Masayoshi
Ishida, Akiko
Abrégé
In order to provide an antibody or antibody fragment including the variable region of said antibody for the H5 subtypes of the avian influenza virus, an antigen polypeptide, and uses thereof, the present invention provides: an antibody or antibody fragment including the variable region of said antibody, which specifically binds to the HA1 antigen polypeptide of the HA1 region of the H5 subtypes of the avian influenza virus, said antigen polypeptide comprising the amino acid sequence represented by SEQ ID NO: 10; the HA1 antigen polypeptide comprising the amino acid sequence represented by SEQ ID NO: 10; and uses of the antibody and antibody fragment including the variable region of the antibody.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present invention provides an agent for the prevention and/or treatment of lung disease containing a compound having (i) a function for suppressing the transformation of epithelial cells into mesenchymal traits in the lung tissue and/or (ii) a function for suppressing enhancement of mesenchymal traits of fibroblasts in the lung tissue to provide a highly safe agent for the prevention and/or treatment of interstitial pneumonia or pulmonary fibrosis having a high therapeutic effect.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/421 - 1,3-Oxazoles, p. ex. pémoline, triméthadione
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
46.
PEPTIDE HAVING OSTEOBLAST PROLIFERATION-PROMOTING ACTIVITY AND USE THEREOF
In order to provide a novel peptide that has both an osteogenesis-promoting effect and a chondrocyte proliferation-promoting effect, the present invention provides a peptide or a derivative or salt thereof, wherein the peptide has amino acid sequence (a), (b), or (c), 100 or fewer of amino acid residues, and osteoblast proliferation-promoting activity. (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (sequence No. 1). (b) Amino acid sequence having conservative substitution or deletion of 1 to 3 amino acids in the amino acid sequence (a). (c) Amino acid sequence formed from at least four linked amino acids in the amino acid sequence (a) or (b).
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
The present invention provides a novel active ingredient which can be safely used in preventing, ameliorating or treating diseases related to the cartilage such as cartilage damages and cartilage disorders. Since the egg yolk protein hydrolyzate has an effect on chondrocyte proliferation promotion, it is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating joint pain. The egg yolk protein hydrolyzate is a natural-origin material with high safety and, therefore, can be widely used in foods and drinks, medicines, feeds and the like which can be daily ingested.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) (a) Gamma-aminobutyric acid (GABA) for use as a food additive; fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive; (b) dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid and gelled form.
(2) Gamma-aminobutyric acid (GABA) used as an ingredient of soft drinks, sports drinks, and smoothies.
Provided is a novel active ingredient that can be safely used in preventing, ameliorating or treating cartilage-related diseases such as cartilage injuries or cartilage disorders. An egg yolk protein hydrolysate, which has an effect of promoting cartilage cell growth, is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating arthralgia. The egg yolk protein hydrolysate is a natural-origin material with high safety and, therefore, is widely usable in foods, drinks, medicines, feeds and the like that can be daily ingested.
Disclosed are: a novel peptide having an osteoblast proliferation promotion activity; a medicinal agent for promoting the formation of bones, which comprises the peptide; and an excellent use application which utilizes the peptide.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/465 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant d'oiseaux
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
51.
ANTIBODY AND ANTI-PERIODONTAL DISEASE COMPOSITION CONTAINING ANTIBODY
Provided are an antibody which is effective in inhibiting the formation of a biofilm and removing the same and has a high effect against periodontal bacteria; and an anti-periodontal disease composition which contains said antibody. A chicken egg antibody, which is obtained from an avian egg having been immunized with an antigen that is a culture obtained by mixed-culturing two or more kinds of periodontal bacteria, is used as an anti-periodontal disease composition. The periodontal bacteria preferably comprise two or more kinds of bacteria selected from among Porphyromonas gingivalis, Fusobacterium nucleatum, Actinobacillus actinomycetemcomitans, Tannerella forsythensis, Treponema denticola, Prevotella intermedia and Streptococcus gordonii.
An antistress composition of the invention contains -aminobutyric acid and a nucleic acid-related compound as active ingredients and it preferably contains -aminobutyric acid and the nucleic acid-related compound in a mass ratio of 1:0.0001 to 1:0.1. The nucleic acid-related compound is preferably at least one type selected from the group consisting of uracil, uridine, uridylic acid (UMP), uridine 5’-diphosphate (UDP), uridine 5’-triphosphate (UTP), adenine, adenosine, adenylic acid (AMP), adenosine 5’-diphosphate (ADP), adenosine 5’-triphosphate (ATP), inosine, inosinic acid (IMP), inosine 5’-diphosphate (IDP), inosine 5’-triphosphate (ITP), deoxyuridine, deoxyuridylic acid (dUMP), deoxyuridine 5’-diphosphate (dUDP), deoxyuridine 5’-triphosphate (dUTP), deoxyadenosine, deoxyadenylic acid (dAMP), deoxyadenosine 5’-diphosphate (dADP), deoxyadenosine 5’-triphosphate (dATP), deoxyinosine, deoxyinosinic acid (dIMP), deoxyinosine 5’-diphosphate (dIDP), deoxyinosine 5’-triphosphate (dITP), xanthin and salts thereof. The antistress composition of the invention efficiently suppresses/decreases mental fatigue by oral intake, can be expected to have an effect of preventing/improving health disorder caused by the mental fatigue and can be easily formulated into various foods and drinks.
A61K 31/7064 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Gamma-aminobutyric acid (GABA) for use as a food additive; fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive Dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid, and gelled form
MITSUBISHI CORPORATION LIFE SCIENCES LIMITED (Japon)
Inventeur(s)
Yamatsu, Atsushi
Nakamura, Utano
Sakata, Tomoko
Kim, Mujo
Yokoyama, Yasuhiro
Abrégé
Provided is a novel composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing ?-aminobutyric acid.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is an anti-PAD2 antibody which has excellent PAD2 inhibitory activity. The used anti-PAD2 antibody specifically binds to positions 341-357 of PAD2 or specifically binds to a peptide having an amino acid sequence indicated by SEQ ID NO: 1.
Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid sequence of SEQ ID NO: 4, LCDR2 includes an amino acid sequence of SEQ ID NO: 5, and LCDR3 includes an amino acid sequence of SEQ ID NO: 6, or an antibody fragment thereof.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
